Abstract
The structure-activity relationships of azetidine-based DPP IV inhibitors will be discussed in detail in the following review. The azetidine-based DPP IV inhibitors can be divided into three main subtypes, the 2-cyanoazetidines, 3-fluoroazetidines and 2-ketoazetidines. These subtypes have been explored and structure-activity relationships have been established by several groups. Several compounds within each of these subtypes display sub micromolar potency against DPP IV. The most potent cyanoazetidines and ketoazetidines have large, hydrophobic amino acid groups bound to the azetidine nitrogen and display activities below 100nM. DPP IV inhibition is not sensitive to stereochemistry at the 2- position as both 2-(R)- and 2-(S)-cyano and -keto azetidines display similar inhibitory potencies. While these “warhead”- based cyano- and ketoazetidines have the potential for covalent, bond-forming inhibition, they can also react to internally cyclize into inactive ketopiperazines and dihydroketopyrazine. Thus, chemical instability was also explored for compounds in these two subtypes and certain members of the cyanoazetidine series display aqueous stability comparable to the closely related cyanopyrrolidines. Select 3-fluoroazetidines also display inhibitory potencies below 1μM without the propensity for cyclization and chemical instability associated with the other subseries.
Keywords: Pyrrolidine Based DPP IV Inhibitors, ketone-based DPP IV inhibitors, Cyanopyrrolidine, fluoroazetidines, ketopyrrolidines
Current Topics in Medicinal Chemistry
Title: Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV)
Volume: 7 Issue: 6
Author(s): Dana Ferraris, Sergei Belyakov, Weixing Li, Eddie Oliver, Yao-Sen Ko, David Calvin, Susan Lautar, Bert Thomas and Camilo Rojas
Affiliation:
Keywords: Pyrrolidine Based DPP IV Inhibitors, ketone-based DPP IV inhibitors, Cyanopyrrolidine, fluoroazetidines, ketopyrrolidines
Abstract: The structure-activity relationships of azetidine-based DPP IV inhibitors will be discussed in detail in the following review. The azetidine-based DPP IV inhibitors can be divided into three main subtypes, the 2-cyanoazetidines, 3-fluoroazetidines and 2-ketoazetidines. These subtypes have been explored and structure-activity relationships have been established by several groups. Several compounds within each of these subtypes display sub micromolar potency against DPP IV. The most potent cyanoazetidines and ketoazetidines have large, hydrophobic amino acid groups bound to the azetidine nitrogen and display activities below 100nM. DPP IV inhibition is not sensitive to stereochemistry at the 2- position as both 2-(R)- and 2-(S)-cyano and -keto azetidines display similar inhibitory potencies. While these “warhead”- based cyano- and ketoazetidines have the potential for covalent, bond-forming inhibition, they can also react to internally cyclize into inactive ketopiperazines and dihydroketopyrazine. Thus, chemical instability was also explored for compounds in these two subtypes and certain members of the cyanoazetidine series display aqueous stability comparable to the closely related cyanopyrrolidines. Select 3-fluoroazetidines also display inhibitory potencies below 1μM without the propensity for cyclization and chemical instability associated with the other subseries.
Export Options
About this article
Cite this article as:
Ferraris Dana, Belyakov Sergei, Li Weixing, Oliver Eddie, Ko Yao-Sen, Calvin David, Lautar Susan, Thomas Bert and Rojas Camilo, Azetidine-Based Inhibitors of Dipeptidyl Peptidase IV (DPP IV), Current Topics in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/156802607780090993
DOI https://dx.doi.org/10.2174/156802607780090993 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-inflammatory Lipid Mediators Derived from ω-6 and ω-3 Polyunsaturated Fatty Acids as a Treatment Option for IBD
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry QSAR Studies for the Pharmacological Inhibition of Glycogen Synthase Kinase-3
Medicinal Chemistry Role of Metalloproteinases in Tendon Pathophysiology
Mini-Reviews in Medicinal Chemistry Dimeric and Hybrid Anti-Alzheimer Drug Candidates
Current Medicinal Chemistry Neurobehavioral and Cognitive Changes Induced by Sleep Deprivation in Healthy Volunteers
CNS & Neurological Disorders - Drug Targets Depression, Stress Symptoms, and Cortisol Awakening Response in Female Adolescents with Chronic Headache
Adolescent Psychiatry New Insights into Serotonin 5-HT4 Receptors : A Novel Therapeutic Target for Alzheimers Disease?
Current Alzheimer Research Fragile X Syndrome and Alzheimers Disease: Another Story About APP and β -Amyloid
Current Alzheimer Research Low-Temperature Thermal Properties of Channel Water Confined in Nanopores with Hydrophilic Crystalline and Silica Non-Crystalline Walls
Current Inorganic Chemistry (Discontinued) Functional Role of Lipoprotein Receptors in Alzheimers Disease
Current Alzheimer Research Induction of Oral Tolerance with Transgenic Plants Expressing Antigens for Prevention/Treatment of Autoimmune, Allergic and Inflammatory Diseases
Current Pharmaceutical Biotechnology Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enzoinformatics Approach
CNS & Neurological Disorders - Drug Targets Classification of Acetylcholinesterase Inhibitors and Decoys by a Support Vector Machine
Combinatorial Chemistry & High Throughput Screening Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
Current Medicinal Chemistry A Comprehensive Review on the Biological and Pharmacological Activities of Rhodanine Based Compounds for Research and Development of Drugs
Mini-Reviews in Medicinal Chemistry Epigenomic-Basis of Preemptive Medicine for Neurodevelopmental Disorders
Current Genomics Immune System Modulators with Antidepressant Effects: Evidence from Animal Models
CNS & Neurological Disorders - Drug Targets Expression and Function of Cytochrome P450 in Brain Drug Metabolism
Current Drug Metabolism Calcium Homeostasis Following Traumatic Neuronal Injury
Current Neurovascular Research Scope and Limitations of The Co-Drug Approach to Topical Drug Delivery
Current Pharmaceutical Design